刊物主题:Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration; Public Health;
出版者:Springer International Publishing
ISSN:1179-1896
卷排序:15
文摘
Background and ObjectivesThe Göteborg randomised population-based prostate cancer screening trial demonstrated that prostate-specific antigen (PSA)-based screening reduces prostate cancer deaths compared with an age-matched control group. Utilising the prostate cancer detection rates from this study, we investigated the clinical and cost effectiveness of a similar PSA-based screening strategy for an Australian population of men aged 50–69 years.